Carroll Financial Associates’s Intellia Therapeutics NTLA Stock Holding History

Carroll Financial Associates’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$51K	Hold	430	–	–	﹤0.01%	718
2021 Q3	$57K	Hold	430	–	–	﹤0.01%	716
2021 Q2	$69K	Hold	430	–	–	﹤0.01%	698
2021 Q1	$34K	Buy	+430	New	+$28.9K	﹤0.01%	861
2020 Q4	–	Sell	-744	Closed	-$14K	–	1616
2020 Q3	$14K	Hold	744	–	–	﹤0.01%	961
2020 Q2	$15K	Hold	744	–	–	﹤0.01%	929
2020 Q1	$9K	Hold	744	–	–	﹤0.01%	982
2019 Q4	$10K	Hold	744	–	–	﹤0.01%	1067
2019 Q3	$9K	Buy	744 +708	+1,967%	+$11.3K	﹤0.01%	1039
2019 Q2	$0	Hold	36	–	–	﹤0.01%	1663
2019 Q1	$0	Buy	+36	New	+$537	﹤0.01%	1447

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Carroll Financial Associates's NTLA Position: Q4 2021 in Review

Carroll Financial Associates held its Intellia Therapeutics (NTLA) position steady in Q4 2021 at 430 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #718.

Carroll Financial Associates first reported a position in NTLA in Q1 2019 and has held it in 11 quarters since. The position peaked at $69K in Q2 2021. 372 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

Carroll Financial Associates held 430 shares of Intellia Therapeutics worth $51K as of Q4 2021.
Carroll Financial Associates left its Intellia Therapeutics share count unchanged in Q4 2021.
Intellia Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #718 holding.
Carroll Financial Associates first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 11 quarters since.
Carroll Financial Associates's Intellia Therapeutics position peaked at $69K in Q2 2021.
372 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.